Iovance Biotherapeutics Overview
Iovance Biotherapeutics Target Price
Analysts' 12-month price predictions for IOVA.
Share Price
$1.75
Average Target Price
$6.75
285.7% upside
285.7% upside2 analysts in the last 4 months
High: $7.5 | Low: $6
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-02-28 | Piper Sandler | $6 | 242.9% upside |  |
| 2025-01-31 | Piper SandlerJoseph Catanzaro | $7.5 | 328.6% upside | |
| 2024-10-24 | UBSDavid Dai | $17 | 871.4% upside | |
| 2024-08-09 | Stifel NicolausBenjamin Burnett | $11.5 | 557.1% upside | |
| 2024-08-09 | Robert W. BairdColleen Kusy | $12 | 585.7% upside | |
| 2024-07-29 | Piper SandlerJoseph Catanzaro | $10 | 471.4% upside | |
| 2024-06-20 | JMP SecuritiesReni Benjamin | $11.5 | 557.1% upside | |
| 2024-05-31 | Stifel NicolausBenjamin Burnett | $14 | 700% upside | |
| 2024-03-14 | Piper SandlerJoseph Catanzaro | $19 | 985.7% upside | |
| 2022-12-08 | Goldman SachsMadhu Kumar | $6 | 242.9% upside | |
| 2022-11-20 | Piper SandlerJoseph Catanzaro | $11 | 528.6% upside | |
| 2022-08-23 | Robert W. BairdMichael Ulz | $12.5 | 614.3% upside | |
| 2022-07-01 | Goldman Sachs | $18 | 928.6% upside | |
| 2022-05-27 | Stifel Nicolaus | $13 | 642.9% upside | |
| 2022-04-07 | Robert W. BairdColleen Kusy | $34 | 1842.9% upside | |
| 2022-04-05 | Robert W. BairdColleen M. Kusy | $30 | 1614.3% upside | |
| 2022-01-28 | Stifel NicolausBenjamin Burnett | $25 | 1328.6% upside | |
| 2022-01-05 | Wells FargoNick Abbott | $25 | 1328.6% upside | |
| 2021-05-19 | BarclaysPeter Lawson | $40 | 2185.7% upside | |